BioSpace News Archive

Cyanotech® Corporation, (Nasdaq Capital Market: CYAN), a world leader in microalgae-based, high-value nutrition and health products, announces its launch of BioAstin® Hawaiian Astaxanthin® in a new delivery form, water dispersible powder, available in both 1% and 2% concentrations.

Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in a fireside chat at Chardan’s Virtual 4 th Annual Genetic Medicines Conference 2020 on M

ViewRay, Inc. announced that the Company will host a virtual physician-led informational discussion for investors and analysts during the 2020 American Society of Radiation Oncology Annual Meeting.

- Evaluating 3 doses of olorinab in study participants with the clinical diagnosis of irritable bowel syndrome with predominant constipation (IBS-C) or diarrhea (IBS-D) - Topline data expected Q1 2021 - Significant unmet need for non-opioid, peripherally acting pain management in gastrointestinal disorders [01-October-2020] SAN DIEGO , Oct. 1, 2020

DexCom, Inc. announced that it plans to release its third quarter 2020 financial results after market close on Tuesday, October 27, 2020.

Proceeds Will Be Allocated to Support Regulatory Activities Associated with the Company’s Development Pipeline, Including Funding the Pivotal Clinical Trial for Mytesi for Cancer Therapy-Related Diarrhea (CTD)

Advanced Dermatology and Cosmetic Surgery announced that Dermatology Associates of Montgomery – the practice of Drs. J. Stephen Maddox and E. Ann Mountcastle, located at 286 Mitylene Park Dr, in Montgomery, AL – has joined the organization as its latest affiliate

Johnson & Johnson (NYSE: JNJ) today announced it has successfully completed its acquisition of Momenta Pharmaceuticals, Inc. (“Momenta”), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 billion.

UHN will utilize VoxNeuro’s neurotechnology to generate objective quantifiable data to study the improvement in all core brain functions

Researchers at Intermountain Healthcare in Salt Lake City have developed a new clinical tool to accurately identify and diagnose COVID-19 patients who are at high risk of developing a serious inflammatory condition that can damage the lungs and other organs.